Besides the physiological role of histone deacetalylases in maintaining normal cellular integrity, the acetylation landscape is changed in cancer cells, which has been implicated as a potential target in cancer therapy. The overexpression of certain HDACs correlates with specific cancer types. Therefore, the development of specific HDAC inhibitors may extend the therapeutic strategy for cancer therapy. Here, we describe how to investigate the therapeutic potential of specific HDACi by treatment in a mouse model for B-cell lymphoma, exemplified by the HDAC6 inhibitor Marbostat-100.
Keywords: B-cell lymphoma; Flow cytometry; HDACi; Lymphomagenesis; Mouse model; Tumor progression.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.